Use of clofarabine for acute childhood leukemia

A Pession, R Masetti, K Kleinschmidt, A MartoniPediatric Oncology and Hematology &ldquo;Lalla Ser&agrave;gnoli&rdquo;, University of Bologna, ItalyAbstract: A second-generation of purine nucleoside analogs, starting with clofarabine, has been developed in the course of the se...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A Pession, R Masetti, K Kleinschmidt, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b9b81dd906ce4f908af6e9d88f53afc4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b9b81dd906ce4f908af6e9d88f53afc4
record_format	dspace
spelling	oai:doaj.org-article:b9b81dd906ce4f908af6e9d88f53afc42021-12-02T03:41:09ZUse of clofarabine for acute childhood leukemia1177-54751177-5491https://doaj.org/article/b9b81dd906ce4f908af6e9d88f53afc42010-06-01T00:00:00Zhttp://www.dovepress.com/use-of-clofarabine-for-acute-childhood-leukemia-a4654https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491A Pession, R Masetti, K Kleinschmidt, A MartoniPediatric Oncology and Hematology &ldquo;Lalla Ser&agrave;gnoli&rdquo;, University of Bologna, ItalyAbstract: A second-generation of purine nucleoside analogs, starting with clofarabine, has been developed in the course of the search for new therapeutic agents for acute childhood leukemia, especially for refractory or relapsed disease. Clofarabine is a hybrid of fludarabine and cladribine, and has shown to have antileukemic activity in acute lymphoblastic leukemia as well as in myeloid disorders. As the only new antileukemic chemotherapeutic agent to enter clinical use in the last 10 years, clofarabine was approved as an orphan drug with the primary indication of use in pediatric patients. Toxicity has been tolerable in a heavily pretreated patient population, and clofarabine has been demonstrated to be safe, both as a single agent and in combination therapies. Liver dysfunction has been the most frequently observed adverse event, but this is generally reversible. Numerous Phase I and II trials have recently been conducted, and are still ongoing in an effort to find the optimal role for clofarabine in various treatment strategies. Concomitant use of clofarabine, cytarabine, and etoposide was confirmed to be safe and effective in two independent trials. Based on the promising results when used as a salvage regimen, clofarabine is now being investigated for its potential to become part of frontline protocols.Keywords: clofarabine, pediatric acute lymphoblastic leukemia, pediatric acute myeloid leukemia A PessionR MasettiK Kleinschmidtet alDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 111-118 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 A Pession R Masetti K Kleinschmidt et al Use of clofarabine for acute childhood leukemia
description	A Pession, R Masetti, K Kleinschmidt, A MartoniPediatric Oncology and Hematology &ldquo;Lalla Ser&agrave;gnoli&rdquo;, University of Bologna, ItalyAbstract: A second-generation of purine nucleoside analogs, starting with clofarabine, has been developed in the course of the search for new therapeutic agents for acute childhood leukemia, especially for refractory or relapsed disease. Clofarabine is a hybrid of fludarabine and cladribine, and has shown to have antileukemic activity in acute lymphoblastic leukemia as well as in myeloid disorders. As the only new antileukemic chemotherapeutic agent to enter clinical use in the last 10 years, clofarabine was approved as an orphan drug with the primary indication of use in pediatric patients. Toxicity has been tolerable in a heavily pretreated patient population, and clofarabine has been demonstrated to be safe, both as a single agent and in combination therapies. Liver dysfunction has been the most frequently observed adverse event, but this is generally reversible. Numerous Phase I and II trials have recently been conducted, and are still ongoing in an effort to find the optimal role for clofarabine in various treatment strategies. Concomitant use of clofarabine, cytarabine, and etoposide was confirmed to be safe and effective in two independent trials. Based on the promising results when used as a salvage regimen, clofarabine is now being investigated for its potential to become part of frontline protocols.Keywords: clofarabine, pediatric acute lymphoblastic leukemia, pediatric acute myeloid leukemia
format	article
author	A Pession R Masetti K Kleinschmidt et al
author_facet	A Pession R Masetti K Kleinschmidt et al
author_sort	A Pession
title	Use of clofarabine for acute childhood leukemia
title_short	Use of clofarabine for acute childhood leukemia
title_full	Use of clofarabine for acute childhood leukemia
title_fullStr	Use of clofarabine for acute childhood leukemia
title_full_unstemmed	Use of clofarabine for acute childhood leukemia
title_sort	use of clofarabine for acute childhood leukemia
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/b9b81dd906ce4f908af6e9d88f53afc4
work_keys_str_mv	AT apession useofclofarabineforacutechildhoodleukemia AT rmasetti useofclofarabineforacutechildhoodleukemia AT kkleinschmidt useofclofarabineforacutechildhoodleukemia AT etal useofclofarabineforacutechildhoodleukemia
_version_	1718401694185816064

Use of clofarabine for acute childhood leukemia

Ejemplares similares